AstraZeneca, the Anglo-Swedish pharmaceutical giant, has set an ambitious target of reaching $80 billion in total Revenue by 2030. This represents a significant 75% increase from their 2023 revenue of $45.8 billion. This bold move signifies their confidence in their robust drug development pipeline and the potential of their existing portfolio in oncology, biopharmaceuticals, and rare diseases. The company’s strategy hinges on two key pillars: launching 20 new medicines by the decade’s end and fostering continued growth within its core
